The role of the sympathetic nervous system in the pathogenesis of cardiovascular disease was examined in the article. The opportunities of β-blockers, in particular betaxolol, in controlling of harmful effects of chronic sympathetic hyperactivation on cardiovascular system were described. The data of studies that demonstrate high clinical efficacy of betaxolol in treatment of cardiovascular diseases were demonstrated.